![](/images/graphics-bg.png)
Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
Joint Authors
Hajighasemlou, Saieh
Nikbakht, Mohsen
Pakzad, Saeedreza
Muhammadnejad, Samad
Gharibzadeh, Safoora
Mirmoghtadaei, Milad
Zafari, Fariba
Seyhoun, Iman
Ai, Jafar
Verdi, Javad
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-06-15
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide.
Sorafenib (Sora) is used as a targeted therapy for HCC treatment.
Mesenchymal stem cells (MSCs) are applied as a new approach to fight malignancies.
Drug resistance and side effects are the major concerns with Sora administration.
The effect of using the combination of sorafenib and MSCs on tumor regression in xenograft HCC models was evaluated in this study.
Methods and Materials.
Human hepatocellular carcinoma cell lines (HepG2) were subcutaneously implanted into the flank of 18 nude mice.
The animals were randomly divided into six groups (n = 3); each received Sora (oral), MSCs (IV injection), MSCs (local injection), Sora + MSCs (IV injection), Sora + MSCs (local injection), or no treatment (the control group).
Six weeks after tumor implantation, the mice were scarified and tumoral tissues were resected in their entirety.
Histopathological and immunohistochemical evaluations were used to measure tumor proliferation and angiogenesis.
Apoptotic cells were quantified using the TUNEL assay.
Results.
No significant difference was found in the tumor grade among the treatment groups.
Differentiation features of the tumoral cells were histopathologically insignificant in all the groups.
Tumor necrosis was highest in the hpMSC (local) + Sora group.
Tumor cell proliferation was reduced in hpMSC (local) + Sora-treated and hpMSC (IV) + Sora-treated mice compared with the other groups.
Apoptotic-positive cells occupied a greater proportion in the Sora, hpMSC (IV) + Sora, and hpMSC (local) + Sora groups.
Conclusion.
A combination of chemotherapy and MSC can yield to more favorable results in the treatment of HCC.
American Psychological Association (APA)
Hajighasemlou, Saieh& Nikbakht, Mohsen& Pakzad, Saeedreza& Muhammadnejad, Samad& Gharibzadeh, Safoora& Mirmoghtadaei, Milad…[et al.]. 2020. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1158628
Modern Language Association (MLA)
Hajighasemlou, Saieh…[et al.]. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1158628
American Medical Association (AMA)
Hajighasemlou, Saieh& Nikbakht, Mohsen& Pakzad, Saeedreza& Muhammadnejad, Samad& Gharibzadeh, Safoora& Mirmoghtadaei, Milad…[et al.]. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1158628
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1158628